Jan. 26, 2024
by Natalia Honchar
Biopharma insight
When we hear “AI in drug discovery”, there is a high chance our imagination would draw a small molecule discovery …
Jan. 26, 2024
by Andrii Buvailo, PhD
Biopharma insight
The year 2024 has ushered in a new wave of excitement in the biotech industry, with several promising companies making …
Jan. 23, 2024
by Andrii Buvailo
Interview
The development of oncology drugs faces significant challenges, including a high failure rate (97%) in clinical trials, due to complex …
We at Receptor.AI are excited to present the next important milestone in the development of our next-generation AI docking model, …
Jan. 15, 2024
by Roman Kasianov
News
Mesenbio, a pioneering biotechnology firm emerging from the University of York, has recently secured a significant £1.4 million investment. This …
Jan. 12, 2024
by Dana Sokolova
Biopharma insight
In 2023, the venture capital (VC) landscape witnessed significant activity, providing crucial support to the biotech sector amidst a volatile …
Jan. 11, 2024
by Illia Petrov
News
Xcell Biosciences, Inc., a notable company in the field of cell and gene therapy applications, has recently unveiled a strategic …
Jan. 7, 2024
by Andrii Buvailo
News
Isomorphic Labs, a digital biology company specializing in AI applications, has entered into two distinct research collaborations with Eli Lilly …
Jan. 7, 2024
by Dana Sokolova
Biopharma insight
With over half of the world's population being female, it's only natural that the world of femtech is experiencing a …
Jan. 5, 2024
by Irina Bilous, Andrii Buvailo
Biopharma insight
The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about 11% …
Jan. 4, 2024
by Andrii Buvailo
News
In a new development in oncology, the Menarini Group and Insilico Medicine have announced an exclusive global licensing agreement. This …
Jan. 3, 2024
by Halyna Buvailo
News
InVivo Biosystems, operating in the realm of CRISPR-edited animal models for biomedical research, has recently embarked on a new phase …